Kidney dosimetry in (177)lu and (90)y Peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors.
Kidney dosimetry in (177)Lu and (90)Y PRRT requires 3 to 6 whole-body/SPECT scans to extrapolate the peptide kinetics, and it is considered time and resource consuming. We investigated the most adequate timing for imaging and time-activity interpolating curve, as well as the performance of a simplif...
| Publicado en: | BioMed Research International Vol. 2013; pp. 935351 - 935352 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Wiley-Blackwell
2013
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104082268&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104082268 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 2013 vid: 2013 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 104082268 104082268 2012190644 NLM23865075 PMC3705840 104082268 ppf: 935351 ppct: 1 formats: fmt: @attributes: type: P tig: atl: Kidney dosimetry in (177)lu and (90)y Peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors. aug: au: Guerriero, F Ferrari, M E Botta, F Fioroni, F Grassi, E Versari, A Sarnelli, A Pacilio, M Amato, E Strigari, L Bodei, L Paganelli, G Iori, M Pedroli, G Cremonesi, M affil: Medical Physics Department, European Institute of Oncology, 20141 Milan, Italy. sug: subj: Kidney Radiography Octreotide Acetate Analogs and Derivatives Organometallic Compounds Pharmacokinetics Radiometry Receptors, Cell Surface Metabolism Aged Aged, 80 and Over Calibration Human Kinetics Middle Age Octreotide Acetate Pharmacokinetics Prospective Studies Risk Factors Time Factors Tomography, Emission-Computed, Single-Photon Tomography, X-Ray Computed Aged: 65+ years Aged, 80 & over Middle Aged: 45-64 years ab: Kidney dosimetry in (177)Lu and (90)Y PRRT requires 3 to 6 whole-body/SPECT scans to extrapolate the peptide kinetics, and it is considered time and resource consuming. We investigated the most adequate timing for imaging and time-activity interpolating curve, as well as the performance of a simplified dosimetry, by means of just 1-2 scans. Finally the influence of risk factors and of the peptide (DOTATOC versus DOTATATE) is considered. 28 patients treated at first cycle with (177)Lu DOTATATE and 30 with (177)Lu DOTATOC underwent SPECT scans at 2 and 6 hours, 1, 2, and 3 days after the radiopharmaceutical injection. Dose was calculated with our simplified method, as well as the ones most used in the clinic, that is, trapezoids, monoexponential, and biexponential functions. The same was done skipping the 6¿h and the 3¿d points. We found that data should be collected until 100¿h for (177)Lu therapy and 70¿h for (90)Y therapy, otherwise the dose calculation is strongly influenced by the curve interpolating the data and should be carefully chosen. Risk factors (hypertension, diabetes) cause a rather statistically significant 20% increase in dose (t-test, P < 0.10), with DOTATATE affecting an increase of 25% compared to DOTATOC (t-test, P < 0.05). pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|